Alexandria Real Estate Equities
ARE
$52.72
+2.11%
Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT) specializing in the ownership, development, and operation of collaborative life science and technology campuses in key innovation clusters across the United States, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. As a market leader in the life science real estate niche, the company differentiates itself through its deep tenant relationships and strategic focus on high-barrier-to-entry urban submarkets. The current investor narrative centers on the company's transition through a challenging period marked by significant net losses and a sharp decline in its stock price, while management works to reposition its portfolio and navigate headwinds in the office and lab space market. Recent attention has focused on the company's financial performance, including a substantial fourth-quarter loss, and the broader implications for its dividend sustainability and long-term growth strategy.…
ARE
Alexandria Real Estate Equities
$52.72
Investment Opinion: Should I buy ARE Today?
Rating: Hold. The stock is currently rated 'Hold' by analysts with an average target price of $53.00, implying a modest 2.8% upside. The thesis is that while the company faces significant near-term challenges, the deep valuation discount and stable revenue provide some downside protection, but the lack of clear catalysts for recovery warrants caution.
Sign up to view all
ARE 12-Month Price Forecast
The AI assessment is bearish due to the company's severe profitability challenges and negative momentum. The deep valuation discount is not enough to offset the operational losses and high leverage. The stance would upgrade to neutral if the company reports positive EPS and revenue growth stabilizes, or to bullish if the life science market recovers strongly and the company returns to profitability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alexandria Real Estate Equities's 12-month outlook, with a consensus price target around $53.00 and implied upside of +0.5% versus the current price.
Average Target
$53.00
0 analysts
Implied Upside
+0.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$47 - $60
Analyst target range
The target price range spans from a low of $47.00 to a high of $60.00, indicating a wide dispersion of views on the stock's future. The low target suggests potential downside of 8.9% from current levels, possibly reflecting concerns about continued operational losses and dividend sustainability, while the high target implies upside of 16.3%, likely assuming a recovery in the life science real estate market and successful portfolio repositioning. The wide spread between the low and high targets highlights significant uncertainty, and the recent downgrade by BMO Capital suggests some analysts are becoming more cautious, while others remain optimistic about the long-term fundamentals.
Bulls vs Bears: ARE Investment Factors
The bear case currently holds stronger evidence, as the company faces severe profitability challenges, a massive net loss, and a persistent downtrend. The bull case rests on the deep valuation discount and stable revenue, but these are overshadowed by the operational losses and high leverage. The most important tension is whether the Q4 2025 loss is a one-time impairment event or a sign of structural decline. If the losses are transitory and the life science market recovers, the stock could rebound significantly; if not, further downside is likely.
Bullish
- Deep Discount to Historical Valuation: The PS ratio of 2.81 is a significant discount to the historical range of 11.05-59.54, suggesting the market has priced in substantial pessimism. This could offer a margin of safety if the company's earnings power recovers.
- Stable Revenue Base: Quarterly revenue has remained relatively stable, with Q4 2025 revenue of $754.4 million only 1.16% below the prior year. This stability indicates that the core leasing business is not collapsing despite the broader downturn.
- High Gross Margins: Gross margin remains robust at 69.2% in Q4 2025, reflecting the high-quality nature of the life science properties. This provides a solid foundation for potential profitability once impairment charges subside.
- Positive Free Cash Flow: The company generated $1.41 billion in trailing twelve-month free cash flow, which is critical for sustaining the dividend and funding operations during the downturn. This cash generation supports the current dividend yield of 10.9%.
Bearish
- Severe Net Losses: Q4 2025 net loss of $1.08 billion, driven by $2.1 billion in other expenses, resulted in a net margin of -143.4%. This massive loss has eroded investor confidence and raised questions about the sustainability of the business model.
- Negative Operating Margin: Operating margin was -40.5% in Q4 2025, a dramatic deterioration from positive margins in 2024. This indicates that the core operations are not generating sufficient income to cover expenses, excluding the one-time charges.
- Persistent Downtrend: The stock is down 36.98% over the past year, significantly underperforming the S&P 500's gain of 18.56%. The price is near the lower end of its 52-week range, reflecting persistent selling pressure and negative momentum.
- High Debt Levels: The debt-to-equity ratio of 0.82 and EV/Sales of 8.95 indicate a significant debt burden. This leverage increases financial risk, especially if revenue declines or interest rates remain elevated.
ARE Technical Analysis
ARE is currently in a pronounced downtrend, with the stock price down 36.98% over the past year, significantly underperforming the S&P 500's gain of 18.56% over the same period. The current price of $51.57 sits at approximately 58.4% of its 52-week range, which spans from a low of $39.41 to a high of $88.24. This positioning suggests the stock is closer to its lows than its highs, reflecting persistent selling pressure and a bearish sentiment that has driven the price well below its historical peaks.
Beta
1.17
1.17x market volatility
Max Drawdown
-53.8%
Largest decline past year
52-Week Range
$39-$88
Price range past year
Annual Return
-34.8%
Cumulative gain past year
| Period | ARE Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +1.0% |
| 3m | -0.8% | +1.1% |
| 6m | +3.9% | +13.8% |
| 1y | -34.8% | +19.5% |
| ytd | +7.7% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARE Fundamental Analysis
Revenue has remained relatively stable, with the most recent quarterly revenue of $754.4 million representing a slight year-over-year decline of 1.16%, while the previous quarters showed sequential growth from $735.8 million in Q3 2025 to $754.4 million in Q4 2025. However, the company reported a net loss of $1.08 billion in Q4 2025, a dramatic swing from a net income of $167.9 million in Q3 2024, driven by a massive $2.1 billion in other expenses, which included significant impairment charges. This has resulted in a negative net margin of -143.4% for the quarter, a stark contrast to the positive margins seen in 2024, indicating severe profitability challenges.
Quarterly Revenue
$754414000.0B
2025-12
Revenue YoY Growth
-1.2%
YoY Comparison
Gross Margin
69.2%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARE Overvalued?
Given the negative net income, the trailing PE ratio is not meaningful, so we focus on the price-to-sales (PS) ratio, which stands at 2.81 based on current market cap and trailing revenue. This is a significant discount to the historical PS ratios, which have ranged from 11.05 to 59.54 over the past several years, indicating that the market is valuing the stock at a much lower multiple relative to sales than it has historically. The forward PE is also negative at -63.67, reflecting expected continued losses, while the EV/Sales ratio of 8.95 suggests that enterprise value is still high relative to revenue, partly due to debt.
PE
-5.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~176x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
57.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated, with a net loss of $1.08 billion in Q4 2025 and a negative operating margin of -40.5%. The company's debt-to-equity ratio of 0.82 and EV/Sales of 8.95 indicate high leverage, which could strain cash flows if interest rates remain high. The negative payout ratio of -63.7% suggests the dividend is not covered by earnings, though free cash flow of $1.41 billion provides some buffer. Revenue concentration in the life science sector adds vulnerability to sector-specific downturns.